BioSpace News Archive

LEO Pharma A/S announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI 100 score for longer than those who were treated with ustekinumab over 52 weeks.

Software and services donation will back expansion of PATH-led initiative in up to six countries across sub-Saharan Africa

Applied StemCell, Inc. announced that its therapeutic division has cured Hemophilia A in mice and will be presenting their in vivo and in vitro findings at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy held April 29 – May 2 in Washington D.C.

First-In-Human Clinical Study Will be Initiated Later in Second Quarter 2019

1Q19 total revenues of $1,140.4 million, a 23 percent increase over 1Q18 and a 26 percent volume increase

Regulatory submission triggers $10 million milestone payment to Exelixis under collaboration and license agreement with Takeda

Shareholder rights law firm Johnson Fistel, LLP reminds investors that a class action lawsuit has been filed against Boston Scientific Corporation on behalf of all purchasers of common stock during the period between February 26, 2015 through April 16, 2019, inclusive.

Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market

One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements

On behalf of the Honourable Ginette Petitpas Taylor, federal Minister of Health, Terry Duguid, Member of Parliament, will announce federal support for an initiative to communicate health risks related to climate change.